首页|小剂量利妥昔单抗联合甲泼尼龙序贯治疗视神经脊髓炎谱系疾病疗效观察

小剂量利妥昔单抗联合甲泼尼龙序贯治疗视神经脊髓炎谱系疾病疗效观察

扫码查看
目的 探讨小剂量利妥昔单抗联合甲泼尼龙序贯治疗视神经脊髓炎谱系疾病(NMOSD)的临床疗效。方法 选取医院 2017 年1 月至 2020 年 6 月收治的NMOSD患者 112 例,随机分为观察组和对照组,各 56 例。两组患者均予注射用甲泼尼龙琥珀酸钠静脉冲击治疗(1 000 μg/d)3~5 d,逐渐减至125 mg/d,后改为口服甲泼尼龙片 48 mg/d(继续减量至 4 mg/d维持或停用);观察组患者加用利妥昔单抗注射液 100 mg静脉滴注,每周 1 次,连续治疗 4 周,6~12 个月重复使用。结果 治疗后,观察组患者年复发率、扩展残疾状态量表(EDSS)评分均显著低于对照组(P<0。05),外周血T淋巴细胞CD3+和CD4+水平及CD4+/CD8+均显著高于对照组(P<0。05),血清白细胞介素 6(IL-6)、白细胞介素 17(IL-17)及肿瘤坏死因子-α(TNF-α)水平均显著低于对照组(P<0。05)。两组患者治疗后的天门冬氨酸氨基转移酶、丙氨酸氨基转移酶、血尿素氮、血清肌酐水平均无显著改变(P>0。05)。观察组与对照组不良反应发生率相当(7。14%比 12。50%,P>0。05)。结论 小剂量利妥昔单抗联合甲泼尼龙序贯治疗NMOSD,能有效改善患者的病情及机体炎症状况,提高免疫功能。
Efficacy Observation of Low-Dose Rituximab Combined with Methylprednisolone in the Sequential Treatment of Neuromyelitis Optica Spectrum Disorders
Objective To investigate the clinical efficacy of low-dose rituximab combined with methylprednisolone in the sequential treatment of neuromyelitis optica spectrum disorders(NMOSD).Methods A total of 112 patients with NMOSD admitted to the hospital from January 2017 to June 2020 were selected and randomly divided into the observation group and the control group,with 56 cases in each group.The patients in the two groups were given the intravenous pulse therapy with Methylprednisolone Sodium Succinate for Injection(1 000 μg/d)for 3-5 d,and the dosage gradually decreased to 125 mg/d,then the above therapy was replaced with oral Methylprednisolone Tablets(48 mg/d),with the dosage decreasing to 4 mg/d for maintenance or drug withdrawal.On this basis,the patients in the observation group were given the intravenous drip with 100 mg of Rituximab Injection for four weeks,once a week,repeating treatment after six to twelve months.Results After treatment,the annual recurrence rate and Expanded Disability Status Scale(EDSS)score in the observation group were significantly lower than those in the control group(P<0.05),the T lymphocytes CD3 +,CD4 + levels and CD4 +/CD8 + in peripheral blood were significantly higher than those in the control group(P<0.05),the serum interleukin-6(IL-6),interleukin-17(IL-17)and tumor necrosis factor-α(TNF-α)levels were significantly lower than those in the control group(P<0.05).After treatment,the aspartate aminotransferase(AST),alanine aminotransferase(ALT),blood urea nitrogen(BUN)and serum creatinine(SCr)levels in the two groups were similar to those before treatment(P>0.05).The incidence of adverse reactions in the observation group was similar to that in the control group(7.14%vs.12.50%,P>0.05).Conclusion Low-dose rituximab combined with methylprednisolone in the sequential treatment of NMOSD can effectively improve the condition and inflammatory status of patients,and improve their immune function.

neuromyelitis optica spectrum disordersrituximablow dosemethylprednisolonesequential treatmentimmune functioninflammatory factor:clinical efficacy

辜忠灵、甘秀红、丁秀英

展开 >

四川省自贡市第四人民医院,四川 自贡 643000

视神经脊髓炎谱系疾病 利妥昔单抗 小剂量 甲泼尼龙 序贯治疗 免疫功能 炎性因子:临床疗效

四川省卫生健康委员会科研课题

20PJ275

2024

中国药业
重庆市食品药品监督管理局

中国药业

CSTPCD
影响因子:1.369
ISSN:1006-4931
年,卷(期):2024.33(2)
  • 17